Alzheimer's disease — NIH Funding Overview

Why this matters now

Alzheimer's remains the most common cause of dementia, and federal investment has accelerated since the National Plan to Address Alzheimer's Disease set explicit funding goals. The NIH Alzheimer's budget is reported separately to Congress, which both stabilizes long-range planning and concentrates competition for category-specific awards.

How NIH funds this area

Most Alzheimer's awards flow through R01, P30 (ADRCs), R21, K01/K99, and U01/U19 mechanisms. The page below shows yearly award counts and totals from NIH RePORTER, with the most recent example grants and top funded labs. Numbers reflect awards across all NIH institutes, not only NIA.

Yearly NIH Awards for Alzheimer's disease

Counts and total funding per fiscal year from NIH RePORTER. Recent fiscal years may understate final totals because of reporting lag.

Open the full interactive trends view for Alzheimer's disease →

Top NIH Institutes (last 90 days)

Which NIH institutes funded the most Alzheimer's projects in the most recent 90-day window.

Common Activity Codes (last 90 days)

Which grant mechanisms (R01, R21, U01, P30, etc.) appeared most often for Alzheimer's in the recent period.

Most Active Institutions (last 90 days)

Universities and research organizations with the most Alzheimer's awards in the most recent 90-day window.

1. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — 20 awards
2. MASSACHUSETTS GENERAL HOSPITAL — 19 awards
3. COLUMBIA UNIVERSITY HEALTH SCIENCES — 15 awards
4. UNIVERSITY OF MINNESOTA — 14 awards
5. WASHINGTON UNIVERSITY — 13 awards
6. UNIVERSITY OF MICHIGAN AT ANN ARBOR — 12 awards
7. UNIVERSITY OF WISCONSIN-MADISON — 12 awards
8. UNIVERSITY OF PITTSBURGH AT PITTSBURGH — 10 awards

Recently Awarded Alzheimer's disease Grants

Twelve most recent awards mentioning Alzheimer's, drawn from NIH RePORTER. Click through to Find PIs for the full investigator search.

• Capturing Autobiographical memory formation in People moving Through real-world spaces Using synchronized wearables and intracranial Recordings of EEG

  5R61MH135109-03
  Cory Inman · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, UT · $890,660 · awarded Apr 24, 2026 · R61

  Project Summary This project aims to unlock the potential of combining wearable mobile recording devices, such as smartphones with continuous audio-visual, accelerometry, GPS, subjective report, autonomic physiology, and wearable eye tracking recordings, with precisely synchronized intracranial neural recordings during real-world behaviors. Autobiographical memory (AM) formation is a critical human behavior that has been difficult to study with traditional neuroimaging methods. It involves a range of real-world cognitive processes, including attention, decision making, emotion, episodic memory, social interactions, and navigation. AM refers to memory for one’s own life experiences. AMs are typically more detailed and personal than general episodic memories and due to this feature have thus been difficult to capture as they are being formed, particularly the neural correlates of AM encoding. By studying how the brain processes, encodes, and retrieves verifiable, real-world autobiographical experiences, we hope to gain new insights into cognitive and neural processes that can fail in neurological disorders like Alzheimer’s disease. There is a critical need to develop technical, methodological, and computational approaches to understanding the cognitive and neural mechanisms underlying memory-related behaviors in continuous, complex real-world settings, to then translate this understanding into reliable treatments for enhancing memory or cognition in daily life. The proposed project will take important first steps towards addressing these dire needs with a novel and unique approach to recording directly from the human brain as people navigate and create AMs in the temporal contexts and at the spatial scales of daily life. By capturing electrophysiological recordings synchronized with a novel experiential recording device, our project will take the key translational step needed to push our neuroscientific insights of autobiographical memory from the laboratory to one day restoring real-world memory for those suffering from devastating memory disorders. As neural stimulation tools and techniques for memory enhancement develop, insights from the proposed study will establish the foundation on which to build neuromodulation approaches that can rescue memory during real-world experiences. Thus the proposed research project aims to develop a smartphone-based recording application (CAPTURE app; R61 phase) synchronized with wearables and invasive neural recordings during real-world behaviors like autobiographical memory encoding (R33 phase). We will develop novel recording and analytic methods for integrating multimodal data streams with invasive neural recordings in humans during real-world experiences. Over 2,000 potential research participants have sensing and stimulation devices (i.e., NeuroPace Responsive Neurostimulation System; RNS) chronically implanted in their brains for the treatment of epilepsy in the U.S. Our next-generation tool and approach will allow us to precisely capture real-world behaviors that encompass a variety of cognitive processes like autobiographical memory formation, and synchronize this data with direct neural recordings in humans.

• Social Determinants of Health, Resilience, and Premature Cognitive Aging in End-stage Renal Disease

  3R01AG077888-05S1
  Mara McAdams DeMarco · NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY · $41,556 · awarded Apr 24, 2026 · R01

  Only 13% of the 780,000 adults living with end-stage renal disease (ESRD) have normal cognitive function. We found that 14.0% of ESRD patients aged 35-49 experience severe cognitive impairment and 2.9% have a co- occurring functional dependence suggestive of Alzheimer’s disease and related dementia (AD/ADRD). After dialysis initiation older (≥65) patients experience a 21-25% lifetime risk of AD/ADRD. Younger ESRD patients experience premature cognitive aging requiring the study of cognition and AD/ADRD across the lifespan. Black ESRD patients are more than twice as likely to develop cognitive impairment and 70%-78% more likely to be diagnosed with AD/ADRD; this disparity is comparable to a 10 year increase in age. While social determinants of health (SDOH) are known contributors to health disparities in community-dwelling older adults, its impact on cognitive aging among ESRD patients is understudied. ESRD patients are the ideal population to elucidate these mechanisms: 1) 30% of patients are Black; 2) 87% experience premature cognitive aging; 3) all enroll in a national registry and 65% in Medicare for measurement of institutional SDOH. For all adult ESRD patients in the national registry/Medicare database, we will glean 14 indicators of SDOH across all 5 domains [1) economic stability (median home value; median real estate tax; median gross rent; median monthly mortgage; % owner-occupied homes), 2) education (% attained bachelor’s degree; % attainted high school diploma), 3) health care (medically underserved areas; health professional shortage area), 4) neighborhood built environment (public transportation; % building vacancy; % greenspace), and 5) social/community (social fragmentation; social engagement)] from publicly available data using ZIP code at ESKD diagnosis and capturing changes over time) (Aim 1) and additionally using childhood Zip Codes (Aim 2). Then, we will link these data to our ongoing, NIA-funded, multi-center, prospective cohort study (FAIR, n=5,275) of aging and ESRD to fully characterize SDOH. This is the oldest (>12 years) ESRD cohort study that includes longitudinal measures global and domain specific cognitive function. Aim 1: To estimate the impact of SDOH on incident AD/ADRD. Aim 2: To quantify the contributions of lifecourse SDOH on cognitive impairment and decline. Aim 3: To test whether resilience protects against cognitive impairment and decline. ESRD patients are uniquely vulnerable to premature cognitive aging; SDOH are likely causes of health disparities in cognitive impairment, cognitive decline, and ADRD. By taking a lifecourse approach and engaging community, family, and patient stakeholders in all phases of our study, we will identify feasible targets for improving resilience in the face of SDOH. These potential targets for interventions and policies to counter SDOH will likely generalize to other populations with chronic diseases.

• Rapid Estrogen Signaling in Brain Circuits that Guide Complex Behavior

  2R01NS082179-11A1
  LUKE REMAGE-HEALEY · UNIVERSITY OF MASSACHUSETTS AMHERST, MA · $437,823 · awarded Apr 24, 2026 · R01

  PROJECT SUMMARY Neuromodulators like oxytocin, dopamine, serotonin, and catecholamines regulate the activity of forebrain neurons during sensory and cognitive tasks. This scale of neuromodulation allows neural circuits to dynamically encode and respond to sensory stimuli depending on contexts like parenting, aggression, mating, and stress. Neuromodulators classically enhance stimulus extraction from noisy backgrounds, and this regulation is crucial for learning and memory. A recently-discovered neuromodulatory system - the synthesis and action of ‘neuroestrogens’ by specific neuronal cell types – holds a great deal of promise for sensory perception, memory, and cognitive function. In human patients, estrogens can be beneficial treatments for a variety of neurological disorders, including Parkinson’s disease, Alzheimer’s disease, and epilepsy. Yet because the neuromodulatory perspective of brain estrogen synthesis is relatively new, the therapeutic potential of neuroestrogen signaling itself is untapped. This unmet potential is also hampered by our poor understanding of the cellular and circuit mechanisms for neuroestrogen signaling, and their implications for complex behavior. The research program in this proposal will specifically study how neuroestrogens regulate the cellular, microcircuit, and network interactions between excitatory and inhibitory neurons, and situate these outcomes in ethologically-relevant behaviors. Our proposed experiments will clarify the neural circuit mechanisms for neuroestrogen signaling by unraveling the specific contribution of inhibitory and excitatory neurons, including their chemical and electrical synaptic interactions. The proposed projects will take advantage of recent molecular and technological advances that allow us to genetically target fast-spiking inhibitory neurons and principal excitatory neurons in the songbird forebrain. This work will therefore address a fundamental gap in our understanding of how estrogen production within the brain guides complex behavior, and could ultimately inform the development of highly-targeted estrogen therapies for cognitive and neurological disorders.

• Cognitive prehabilitation to prevent Alzheimer's disease after kidney transplantation

  5K02AG076883-04
  Mara McAdams DeMarco · NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY · $151,740 · awarded Apr 21, 2026 · K02

  ABSTRACT Of the 130,000 older (≥50) kidney transplant (KT) recipients in the US, we have estimated that 19% experience post-KT cognitive decline putting them at elevated risk of Alzheimer’s disease and related dementias (ADRD). Compared to a 10-year ADRD risk of 0.6-0.9% for community-dwelling older adults, the risk of ADRD diagnosis is 1.0%-6.7% for older recipients; overall, 7.2-17.0% of older recipients receive a dementia diagnosis within 10 years of KT. Yet, the true burden of ADRD is substantially higher given that only half of patients who would meet diagnostic criteria for dementia receive a diagnosis. A post-KT ADRD diagnosis leads to disability and dependence, and increases a patient’s risk of mortality 2.4-fold and their risk of graft loss 1.5-fold. Within 10 years of an ADRD diagnosis, 88.6% of older recipients have died and 38.9% have experienced graft loss. These preliminary data arise from my current NIH funded research: 1. Prospective cohort study: 12-year-old study of frailty and cognitive function among KT patients; and 2. RCT: 2x2 factorial RCT of interventions to preserve cognitive function among patients initiating hemodialysis. I have established a strong track record and built a research program at the intersection of aging and renal epidemiology which serves as a foundation for this mid-career Independent Scientist (K02) award application. Through this research I have realized that focusing on physical aging without also understanding cognitive aging provides an incomplete picture of older KT patients. As I transition to more administrative duties in 2022, I am unable to expand to ADRD research and develop collaborative relationships with neurocognitive investigators. This K02 will advance my research career by affording me the opportunity for dedicated time to concentrate efforts on career development to expand my research portfolio to include ADRD. My long-term career objective is to establish a sustainable research program focused on physical and cognitive aging among KT recipients. To accomplish these goals, I seek protected time to acquire the knowledge and skills needed: 1. To integrate ADRD research into my existing research portfolio; 2. To develop scientific protocols to study cognitive prehabilitation for older KT recipients; and 3. To establish a national renal aging research network that will collaborate on new research and mentor junior faculty. By replacing administrative duties with protected time, the K02 mechanism will allow me to achieve my long-term career goal of establishing a sustainable research program focused on physical and cognitive aging among KT patients. I will take full advantage of what the K02 Independent Scientist mechanism offers: training in ADRD research, developing a sustainable research infrastructure, and ultimately impacting the lives of the 100,000 patients who experience physical and cognitive decline while waiting for KT.

• Prenatal and Early Life Antecedents of Personality: An Intergenerational Lifespan Approach

  4R01AG053297-07
  Angelina Sutin · FLORIDA STATE UNIVERSITY, FL · $725,297 · awarded Apr 21, 2026 · R01

  Project Summary Alzheimer’s disease is prevalent at the end of life and remains the only leading cause of death without a cure or way to stop or significantly slow its progression. Prevention remains the best hope for reducing risk of Alzheimer’s disease in older adulthood. Given that Alzheimer’s disease has a complex etiology, with risk factors that range from genetics to the environment, multipronged approaches to prevention will likely be needed for an intervention to be broadly effective. Among the psychosocial risk factors for Alzheimer’s disease, personality traits have emerged as consistent predictors of cognitive health across adulthood. Specifically, higher neuroticism (the tendency to experience negative emotions and vulnerability to stress) and lower conscientiousness (the tendency to be organized, disciplined, and responsible) are associated with worse performance on cognitive tasks, more subjective cognitive complaints, and greater risk of Alzheimer’s disease and related dementias. Even after diagnosis, these traits are associated with behavioral and psychological symptoms at the end of life. Lifespan models of personality and health indicate that personality contributes to long-term health outcomes through both behavioral and clinical pathways. Missing from these models, however, are the antecedents of personality, novel mechanisms that go beyond behavioral and clinical risk factors, and how informant ratings of personality and cognition provide unique information about the target’s cognitive health. This work builds on the success of our previous award that found that personality is shaped by socioeconomic factors and that personality is one mechanism in the pathway from childhood socioeconomic status to adult cognitive health. The purpose of this project is to expand consideration of advantages and disadvantages experienced across the lifespan to include other domains to better understand how the accumulation and interplay of such factors across childhood and adulthood shape adult personality traits. This project will further evaluate socioemotional health and behavioral life skills as novel pathways from personality to cognitive health, which are hypothesized to be mechanisms that go beyond traditional behavioral and clinical risk factors. Finally, this project will also include informant ratings of personality and cognition as an additional source of information that provides unique information about the target’s health. We will address these aims in an established, ongoing longitudinal cohort study. The ultimate goal of this work is to develop a personality-informed intervention to support healthier cognitive aging and reduce risk of Alzheimer’s disease. We seek to build a robust and replicable evidence base for a lifespan model of personality and cognitive health that includes antecedents of personality and mechanisms in this pathway, as a step toward this goal.

• Bridging Research Infrastructure for Dementia Gaps in East Africa (BRIDGE-AFRICA)

  3UG3AG090679-02S2
  VICTOR VALCOUR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA · $142,090 · awarded Apr 21, 2026 · UG3

  Project Summary The proposed work will build research infrastructure for Alzheimer’s disease and related dementias (ADRD) in East Africa. We build on MPI Valcour’s, 10-year history of cognitive research in East Africa and activities of the Atlantic Fellows for Equity in Brain Health (AFEBH) program at UCSF, led by Valcour and Miller (see LOS), which has an 8-year history of investment in training ADRD researchers in the region. To date, AFEBH has trained 34 Atlantic Fellows in Africa, including three working in Kenya and nine working in Ethiopia. These include MPI Zewde working at the University of Addis Ababa and MPI Udeh-Momoh leading research at Aga Khan University in Nairobi. The proposal leads with a harmonized cognitive and clinical assessment protocol across two countries in a manner that can become scalable across Africa within the unique Atlantic Fellow network. During the UG3 phase, we will create the tools and demonstrate feasibility for a harmonized two-country intervention-ready cohort of representative community dwelling individuals at risk for ADRD. This work will include finalizing the creation of a harmonized multidomain cognitive assessment battery underway and supported by UCSF’s AFEBH program and the fortification of collaborative community outreach teams to inform culturally appropriate research enrollment and procedure practices. We will continue to train new African AFEBH at UCSF at no cost to this proposal. In the UH3 phase, we will build out cohorts of 200 controls, 50 patients with dementia, and 200 individuals at risk for ADRD in each country, resulting in 900 total enrollees for future intervention trials. During this phase, we will optimize ADRD diagnostics through examination of culturally adapted cognitive and functional assessment tools in our harmonized battery and plasma biomarkers. Through community engagement, we will determine optimal approaches for dementia prevention leveraging targets highlighted in published modifiable risk factors (e.g., hypertension, physical activity, cognitive stimulation) and determine feasibility in preparation for independent research grant applications (e.g., R01s) focused on multidomain prevention strategies. The application draws further support from the Alzheimer’s Association in the U.S., who has partnered with the AFEBH program at UCSF for 8 years to provide competitively reviewed pilot funds allowing fellows to work in their region ($3.4 M to date). They will also continue to co- deliver with the AFEBH program an international conference to be held in Cape Town, South Africa in 2024 with two additional conferences in Africa in support of this proposal (see LOS, no cost to this proposal). Together, this intensive effort will create the tools and cohorts needed to for substantial neuroscience development for ADRD in Africa.

• How Visuospatial Memory Shapes Perception of Real-World Environments

  5R01MH130529-04
  Caroline Robertson · DARTMOUTH COLLEGE, NH · $410,000 · awarded Apr 21, 2026 · R01

  Project Abstract One long-standing puzzle in neuroscience is how scene perception and spatial memory systems – which are topographically distinct in the brain – interface to enable memory-guided visual behavior. In the context of scene perception, two crucial knowledge gaps remain. First, how does visuospatial memory of the local environment facilitate ongoing scene perception? Second, what are the neural underpinnings of memory-guided scene perception? The current project will tackle these questions by combining head-mounted virtual reality (VR), eye-tracking, and fine-grained within-subject fMRI. We will teach participants immersive, real-world environments and test how memory-guided scene processing is implemented in the brain and behavior. In doing so, we will advance a new mechanistic hypothesis as to the neural basis of memory-based predictive coding for scene processing. Together, this project will produce fundamental knowledge about how stored knowledge about the world influences ongoing perception during naturalistic visual experience, and how the brain accomplishes memory-guided visual behaviors like navigation. The resulting knowledge promises impact for our numerous health conditions such as Alzheimer’s, dementia, macular degeneration, cortical visual impairments, and healthy aging, in which both the visual behaviors and brain regions investigated here are implicated.

• Integrative predictive medicine to identify disease causes, develop cures, and optimize patient care

  5R35GM152245-03
  Cassie Mitchell · GEORGIA INSTITUTE OF TECHNOLOGY, GA · $366,688 · awarded Apr 21, 2026 · R35

  Project Summary/Abstract The Laboratory for Pathology Dynamics was founded on the principle that pathology is multifactorial, multi- scalar, and driven by complex interacting dynamics. This proposal builds and applies new predictive medicine technology that enables multifactorial, multi-scalar data integration to identify disease causes, develop cures, and optimize patient care. Key knowledge gaps addressed include: 1.) integration of siloed relationships for interactive literature-based discovery across 33+ million journal articles, including the development of a comprehensive biomedical knowledge graph software called SemBioSys; 2) high-throughput automated meta- analysis to quantify effect size across cohorts and scales using a combination of newly developed deep learning, active learning, interactive weak supervision and human in the loop artificial intelligence (AI) algorithms into a single interactive software; 3) de novo multimodal machine learning algorithms to investigate multifactorial, multi-scalar disease dynamics; 4) human in the loop methods for enhancing AI accuracy, utility, and interpretability, which leverages our large test bed of diverse high school and undergraduate curators acting as subject matter experts. The developed technology will be applied to a bevy of multifactorial diseases in collaboration with clinicians and experimentalists: neurological diseases (Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Parkinson’s Disease), cancers (adult and pediatric acute and chronic leukemias and solid tumor cancers), cardiovascular disease, and infectious disease. The significance of this project is integrative technology to identify and rank novel disease mechanisms, discover and prioritize novel and repurposed drugs, and to optimally stratify patients for fair and equitable clinical trials that minimize health outcome disparities. The innovation includes new integrative biomedical natural language processing (NLP), multimodal machine learning, and dynamic disease modeling and event sequencing algorithms that can be generalized to all of medicine.

• Summer Undergraduate Research Program (NEUROSURP) in Neuroscience

  5R25NS105143-08
  Huaye Zhang · RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ · $127,300 · awarded Apr 21, 2026 · R25

  Project Summary/Abstract The current proposal is to support a Summer Undergraduate Research Program in Neuroscience (NeuroSURP) mentored by Rutgers University research faculty. The program has three primary aims: (1) To increase student knowledge and appreciation of basic biological research by providing a closely-mentored, hands-on research experience; (2) To increase student knowledge and interest in pursuing careers in research through career development and educational activities; (3) To provide continued advice, support and guidance to program alumni to facilitate post-program career planning and implementation. Twelve undergraduates will be admitted to our program each year beginning 2024. Special consideration will be given to students from historically underrepresented minority and disadvantaged backgrounds including Black, Hispanic, Native American, Pacific Islander, or have physical or mental disabilities, or are from economically and/or socially disadvantaged backgrounds (collectively referred to as URM) that comprise a deep and diverse pool of potential future scientists. The research component of the proposed SURP involves hands-on experimentation in labs with active, nationally recognized and funded research programs in neuroscience with a focus on neurological disorders at Rutgers University. The infrastructure and general organization of the proposed program will be based on an existing program that has been in place for 27 years. Students will work on their own research projects under the close supervision of mentors in their host labs. The proposed SURP is designed to integrate student research experiences and mentoring with weekly meetings comprising training in neuroscience, oral and written presentations, critical reading of manuscripts, Responsible Conduct of Research as well as Rigor and Reproducibility including statistical analysis. In addition, there is a significant career development component during the weekly meetings in which PhD, MD/PhD and MD guest speakers discuss their career paths representing academic research, non-academic research as well as research- related careers. Each year students will present the results of their summer research projects in a symposium that is open to scientists on campus and members of the general public. In addition, the students submit a paper on their project in the format of a manuscript and receive feedback from MPIs. Finally, the Co-directors will maintain close contact with the alumni of our program as we have done for the past 27 years and will continue to provide them with advice and mentoring related to applying to graduate school and their careers. The mentors who will be supervising the students study neurological disorders including Alzheimer's, Parkinson's, multiple sclerosis, autism, traumatic brain injury, spinal cord injury, sensory loss, epilepsy, and stroke. The multidisciplinary research focus of the faculty mentors on the cellular, molecular, and genetic processes underlying developmental and degeneration of the nervous system has implications for the etiology, pathogenesis and progression of neurological disorders.

• Bridging Research Infrastructure for Dementia Gaps in East Africa (BRIDGE-AFRICA)

  3UG3AG090679-02S1
  VICTOR VALCOUR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA · $132,511 · awarded Apr 20, 2026 · UG3

  Project Summary The proposed work will build research infrastructure for Alzheimer’s disease and related dementias (ADRD) in East Africa. We build on MPI Valcour’s, 10-year history of cognitive research in East Africa and activities of the Atlantic Fellows for Equity in Brain Health (AFEBH) program at UCSF, led by Valcour and Miller (see LOS), which has an 8-year history of investment in training ADRD researchers in the region. To date, AFEBH has trained 34 Atlantic Fellows in Africa, including three working in Kenya and nine working in Ethiopia. These include MPI Zewde working at the University of Addis Ababa and MPI Udeh-Momoh leading research at Aga Khan University in Nairobi. The proposal leads with a harmonized cognitive and clinical assessment protocol across two countries in a manner that can become scalable across Africa within the unique Atlantic Fellow network. During the UG3 phase, we will create the tools and demonstrate feasibility for a harmonized two-country intervention-ready cohort of representative community dwelling individuals at risk for ADRD. This work will include finalizing the creation of a harmonized multidomain cognitive assessment battery underway and supported by UCSF’s AFEBH program and the fortification of collaborative community outreach teams to inform culturally appropriate research enrollment and procedure practices. We will continue to train new African AFEBH at UCSF at no cost to this proposal. In the UH3 phase, we will build out cohorts of 200 controls, 50 patients with dementia, and 200 individuals at risk for ADRD in each country, resulting in 900 total enrollees for future intervention trials. During this phase, we will optimize ADRD diagnostics through examination of culturally adapted cognitive and functional assessment tools in our harmonized battery and plasma biomarkers. Through community engagement, we will determine optimal approaches for dementia prevention leveraging targets highlighted in published modifiable risk factors (e.g., hypertension, physical activity, cognitive stimulation) and determine feasibility in preparation for independent research grant applications (e.g., R01s) focused on multidomain prevention strategies. The application draws further support from the Alzheimer’s Association in the U.S., who has partnered with the AFEBH program at UCSF for 8 years to provide competitively reviewed pilot funds allowing fellows to work in their region ($3.4 M to date). They will also continue to co- deliver with the AFEBH program an international conference to be held in Cape Town, South Africa in 2024 with two additional conferences in Africa in support of this proposal (see LOS, no cost to this proposal). Together, this intensive effort will create the tools and cohorts needed to for substantial neuroscience development for ADRD in Africa.

• North American Testis Workshop 2026

  1R13HD122397-01
  Monika Ward · UNIVERSITY OF HAWAII AT MANOA, HI · $20,000 · awarded Apr 20, 2026 · R13

  Project Summary This R13 application requests funds to support the XXVIIIth North American Testis Workshop “Of Flies, Mice, and Men: Novel Models that are Changing our Understanding of Testis Biology”, which will be held from April 15-18, 2026, at the Embassy Suites by Hilton Scottsdale Resort in Scottsdale, Arizona. The Workshop will be held immediately prior to the annual meeting of the American Society of Andrology at the same venue. Since 1972, the North American Testis Workshop has been the foremost international forum for both basic and clinician-scientists to present and discuss their recent findings on the development, regulation, and functions of the testis. The Workshop regularly attracts 150-200 attendees from North America and around the world. It is also an important scientific platform for the next generation of testis biologists; approximately one-third of the Workshop participants are trainees. The requested R13 funds will be used to help defray travel costs for 20 trainees and/or early-career investigators who are selected based on scientific merit of the submitted abstracts. R13 funds will also be used to offset a portion of the accommodation costs for the 15 invited speakers. The main objectives of the Workshop are: 1) to provide a platform for the dissemination and discussion of new discoveries on testis biology, especially novel data obtained using the latest omics strategies as well as new biotechnologies (single cell, gene editing) and models of study (atypical species models, artificial intelligence). By combining multiple strategies, conference participants will be provided with a more complete picture of testis biology at the cellular and molecular levels. It will also inspire and encourage translation of the new knowledge to clinical applications and accelerate drug discovery and therapeutics; (2) to create opportunities for scientific exchange and collaborations among peers to foster career growth and to ensure continued advances in the field of testis biology; (3) to offer a forum for trainees (fellows, postdocs and graduate students) and early-career investigators (within the first five years of independent research) to present their research, receive feedback from established investigators, and build professional relationships, all of which are known to be critical for intellectual, scientific, professional, and academic growth.

• Alzheimer Disease Research Center

  5P30AG066468-07
  Oscar Lopez · UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA · $4,514,197 · awarded Apr 17, 2026 · P30

  Revised Overall Abstract: The University of Pittsburgh Alzheimer’s Disease Research Center (PITT-ADRC) has shown a clear scientific evolution over the past four decades. Since our inception, we have advanced the areas of ADRD neuropsychiatry, genetics, natural history of AD, validation of clinical criteria, and clinicopathological correlations. Further, we have pioneered the development of both fluid and imaging biomarkers for the development of AD pathology, which have transformed AD research. We have used a multidisciplinary approach to better understand the transition from normal cognition to dementia, have explored the biology of AD with psychosis, and have made and contributed to new insights in genetics. These achievements and investment in junior investigators have allowed the PITT-ADRC to develop areas of excellence, which form the foundation of our Center. These are reflected in our cores, and most notably in the number of large and wide-ranging studies we support in these areas, locally, nationally, and internationally. The PITT-ADRC is committed to remain at the forefront of scientific efforts to understand the pathological processes involved in the etiology of AD and regional communities and environmental factors that modify those pathological processes, making the PITT-ADRC a center that works from “Neighborhoods to Neurons”. Along with this innovative research conducted by the PITT-ADRC, we are dedicated to developing strong training programs to promote the careers of young investigators and to create strong ties with the community through a variety of partnership programs, with special emphasis on groups historically excluded from research. The PITT-ADRC is highly committed to leverage the strengths of the network of Centers to provide large numbers of samples and standardized clinical data collection from our participants. The PITT-ADRC has modernized our methodology to improve the accessibility of our database to researchers, and it has been a key player in multiple studies that advanced the understanding of ADRD. Therefore, we provide an excellent environment that enhances cutting-edge research by bringing together a multidisciplinary team of investigators to study AD and other dementias, and to improve health care delivery. The methodology proposed in this application will lead us to the creation of a unique and well-characterized cohort of participants across the clinical spectrum of cognitive disorders assessed with state of the art clinical and biomarker methods. This will allow us to test multiple scientific hypotheses and to examine the short- and long-term public health outcomes of the pathophysiology of cognitive disorders in the adult. The PITT-ADRC will be at the center of the new era of AD research that will require a wealth of clinical and biological data, highly sophisticated fluid and imaging biomarker methodologies, close inter-relationship among centers and institutions, creation and optimization of human resources, and enhanced communication with patients and families.

Related topics

• Aging and longevity
• Mental health and psychiatric research